Prickett Timothy Cr, Howe Peter Rc, Espiner Eric A
Department of Medicine University of Otago Christchurch New Zealand.
School of Biomedical Sciences and Pharmacy University of Newcastle Callaghan Australia.
JBMR Plus. 2023 Mar 1;7(5):e10732. doi: 10.1002/jbm4.10732. eCollection 2023 May.
C-type natriuretic peptide (CNP) is a paracrine growth factor essential in driving endochondral bone growth in mammals including humans. Despite evidence from animal experiments and tissues that CNP signaling stimulates osteoblast proliferation and osteoclast activity, whether CNP participates in bone remodeling in the mature skeleton is unknown. Using stored plasma samples from a previous randomized controlled clinical trial (RESHAW) of resveratrol supplementation in postmenopausal women exhibiting mild osteopenia, we have studied changes in plasma aminoterminal proCNP (NTproCNP) and concurrent change in bone turnover markers of formation (osteocalcin [OC] and alkaline phosphatase [ALP]) and resorption (C-terminal telopeptide type 1 collagen [CTX]) with bone mineral density (BMD) over a 2-year period of study in 125 subjects. In year one, subjects received placebo or resveratrol, switching to resveratrol or placebo, respectively, in year two. Across all time points, there were no significant associations of NTproCNP with CTX, ALP, or OC. During year one, plasma NTproCNP declined significantly in both groups. In the crossover comparison, analysis of change within individuals showed that, compared with placebo, NTproCNP declined after resveratrol ( = 0.011) and ALP increased ( = 0.008), whereas CTX and OC were unchanged. Inverse association of NTproCNP ( = -0.31; = 0.025) and positive association of OC ( = 0.32, = 0.022) with BMD at the lumbar spine were identified after resveratrol but not found after placebo. Decline in NTproCNP was independently associated with resveratrol treatment. This is the first evidence that CNP is modulated during a period of increasing BMD in postmenopausal women. Further study of NTproCNP and associations with drivers of bone formation or resorption can be expected to clarify CNP's role during other interventions directed to bone health in adults. © 2023 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
C型利钠肽(CNP)是一种旁分泌生长因子,对包括人类在内的哺乳动物软骨内骨生长至关重要。尽管动物实验和组织研究表明CNP信号传导可刺激成骨细胞增殖和破骨细胞活性,但CNP是否参与成熟骨骼的骨重塑尚不清楚。我们利用来自一项先前的随机对照临床试验(RESHAW)的储存血浆样本,该试验对表现出轻度骨质减少的绝经后妇女补充白藜芦醇,在125名受试者中进行了为期2年的研究,观察血浆氨基端前体CNP(NTproCNP)的变化以及骨形成(骨钙素[OC]和碱性磷酸酶[ALP])和骨吸收(I型胶原C端肽[CTX])的骨转换标志物与骨密度(BMD)的同步变化。在第一年,受试者接受安慰剂或白藜芦醇,在第二年分别改为白藜芦醇或安慰剂。在所有时间点,NTproCNP与CTX、ALP或OC均无显著关联。在第一年,两组血浆NTproCNP均显著下降。在交叉比较中,个体内变化分析显示,与安慰剂相比,白藜芦醇治疗后NTproCNP下降(P = 0.011),ALP升高(P = 0.008),而CTX和OC无变化。白藜芦醇治疗后发现NTproCNP与腰椎BMD呈负相关(r = -0.31;P = 0.025),OC与腰椎BMD呈正相关(r = 0.32,P = 0.022),而安慰剂治疗后未发现。NTproCNP的下降与白藜芦醇治疗独立相关。这是首次有证据表明绝经后妇女在骨密度增加期间CNP受到调节。进一步研究NTproCNP及其与骨形成或骨吸收驱动因素的关联,有望阐明CNP在针对成人骨骼健康的其他干预措施中的作用。© 2023作者。由Wiley Periodicals LLC代表美国骨与矿物质研究学会出版。